Stroke Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been clinically diagnosed with an acute ischemic stroke (a stroke caused by a blocked blood vessel) and where guidelines indicate a clot-dissolving treatment given through a drip is appropriate
- People whose stroke symptoms started, or who were last seen to be well, less than 12 hours ago
- People whose stroke severity score on a standard medical scale (called the NIHSS) is 2 points or higher at the time of admission
- People who have taken a blood-thinning medication called a DOAC within the past 48 hours before the planned clot-dissolving treatment, or who have an ongoing DOAC prescription but the exact time of the last dose cannot be confirmed in the emergency setting, or people with a DOAC prescription (with any intake in the last 7 days) who are receiving the clot-dissolving drip treatment
- People who have given informed consent to participate, where this is required by law or is possible to obtain at the time (confirm with trial site)
Who may not be able to join:
- People who have refused to allow their biological data to be used for research purposes (applies in Switzerland)
- People who have any recent or ongoing bleeding inside the skull, as identified by a brain scan (CT or MRI) taken at admission
- People whose medical records show any other absolute reason that the clot-dissolving drip treatment cannot be given
- People who had significant disability before the stroke, including those with a known advanced stage of dementia (confirm with trial site regarding the specific disability scoring used)
- People with a known serious allergic reaction or sensitivity to the clot-dissolving medications Alteplase or Tenecteplase, or to any of their ingredients
- People who are pregnant or currently breastfeeding
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Thomas Meinel, MD, PhD, Insel Gruppe AG, University Hospital Bern
Phone: +41 31 66 4 25 67
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Number of Participants with symptomatic intracerebral hemorrhage (sICH); Dichotomized good functional outcome (mRS 0-2)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.